CDC Revises Adult Immunization Schedule to Include RSV Vaccination Recommendations for Adults 60 and Older

CDC Updates 2024 Adult Immunization Schedule With RSV Recommendations for Older Adults

The CDC issued its 2024 adult immunization schedule with explicit RSV vaccination guidance for older adults. All adults aged 75 years and older now qualify for a single dose. Adults 60 to 74 years old qualify only if they face increased risk of severe RSV disease. The update replaces the prior shared clinical decision-making approach used for everyone 60 and older. It draws from ACIP votes completed in February 2024. [1][2]

Three vaccines now appear in the routine schedule.
The FDA approved the first RSV vaccine for older adults in May 2023. That product, Arexvy from GSK, was followed by Abrysvo from Pfizer and mResvia from Moderna. All three are included in the 2024 adult schedule for eligible individuals. [3]

Risk-based criteria guide decisions for adults 60 to 74.
The MMWR report ties eligibility in this group to chronic medical conditions or frailty that raise the chance of severe outcomes from RSV. The guidance focuses on those groups while data on longer-term protection continue to develop. [2]

Guidance reflects a deliberate shift in strategy.
The 2023 schedule had suggested shared clinical decision-making for any adult 60 or older. The current version narrows that approach and sets firm thresholds at age 75 while keeping a risk lens for adults 60 to 74. ACIP members examined disease burden, vaccine efficacy against lower respiratory tract disease, and implementation feasibility before finalizing the new wording. [1][2]

What this means

The revised schedule supplies explicit eligibility language that may simplify discussions between providers and patients. It concentrates recommendations where RSV-related hospital stays and complications occur most often. Longer-term protection data and real-world uptake figures are still being gathered.

Key takeaways

• RSV causes substantial morbidity and mortality in older adults, justifying targeted vaccination. [2]
• The three approved RSV vaccines demonstrate efficacy against lower respiratory tract disease in adults ≥60 years. [3]
• Updated guidance shifts from universal shared decision-making to age- and risk-based recommendations to improve implementation. [2]
• A single dose is currently advised. Revaccination guidance will be revisited with additional data. [1]
• Recommendations rest on one season of efficacy results from clinical trials. [2]

Limitations

Recommendations are based on one-season efficacy data. Duration of protection beyond one to two years remains under study. Rare adverse events such as inflammatory neurologic events require continued post-licensure monitoring. Vaccine uptake, insurance coverage, and provider adoption data are not yet available for the newest guidance.

FAQ

Which specific RSV vaccines are now included in the CDC adult schedule?
Arexvy (GSK), Abrysvo (Pfizer), and mResvia (Moderna) are listed for adults who meet the age or risk criteria. [3]

What risk factors qualify adults aged 60–74 for RSV vaccination?
Increased risk linked to chronic conditions or frailty that heighten the likelihood of severe RSV disease. [2]

How does the 2024 RSV guidance differ from the 2023 recommendations?
The prior schedule applied shared clinical decision-making to all adults 60 and older. The 2024 version uses a single-dose recommendation for everyone 75 and older and limits the 60-to-74 group to those at elevated risk. [1][2]

What supporting evidence from ACIP informed the schedule update?
ACIP reviewed disease burden data, vaccine efficacy against lower respiratory tract illness, safety signals, and implementation questions during its October 2023 to February 2024 meetings. [2]